
Sumitomo Pharma Stock Slides After Rally Even as Japan Backs Breakthrough Cell Therapy
Profit-taking hits shares following a massive run-up, while investors weigh the long timeline to commercialization of regenerative treatments
249 articles

Profit-taking hits shares following a massive run-up, while investors weigh the long timeline to commercialization of regenerative treatments

Chip giant’s divestment closes a chapter that began with a failed $40 billion takeover attempt, while long-term technology ties remain intact.

Investor optimism returns as order growth and long-term platform strategy offset weak guidance

A modest rally ends the company’s longest losing streak in nearly two decades as investors weigh massive AI spending against long-term growth potential.

Final filings from Warren Buffett’s CEO tenure reveal modest tech reduction and a fresh media investment

Solid revenue growth and major acquisitions fail to offset investor concerns over weaker near-term earnings guidance

Gucci still struggles, but luxury conglomerate sees a path to growth as new leadership tackles debt, brand repositioning, and strategic expansion

Macquarie-led acquisition values the logistics giant at over A$11 billion, signaling strong investor confidence in infrastructure assets

CEO points to trade-related “exogenous shock” from major retail advertisers despite record 619 million monthly active users

Grocery delivery leader posts fastest gross transaction growth in three years as enterprise platform and AI investments gain traction

Stock slides 5%, erasing 2026 gains amid regulatory pressure on Apple News and uncertainty around flagship AI rollout

Investors cheer Prime Minister Sanae Takaichi’s decisive mandate while broader Asia shrugs off strong U.S. jobs data

Fresh model launches from Zhipu, MiniMax, DeepSeek, Ant Group and ByteDance fuel investor optimism while policymakers double down on AI commercialization

Ride-hailing company misses Wall Street expectations on sales and user metrics despite strong bookings and $1 billion buyback approval

Biotech heavyweight names interim chief as earnings tumble 81% and investors react to restructuring charges and softer vaccine demand

AI connectivity chipmaker posts 92% revenue growth and bullish 2026 outlook, but shares fall on softer expectations and CFO transition